The failed confirmatory trial for AMAG Pharmaceuticals Inc.'s Makena leaves the US Food and Drug Administration with a no-win decision on whether to withdraw the only approved drug for preventing recurrent preterm birth.
However, the experience with the PROLONG trial could have an impact beyond just Makena, potentially making the agency more cautious...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?